We Advance Science

Our mission is to develop lifesaving accessible immunotherapies for the most prevalent diseases plaguing humanity

Tevogen has evolved into next-gen biotech with core organizational capabilities, robust IP portfolio, promising research pipeline, completed lead T cell product POC trial, and received global recognition for its patient centric, purpose driven business model – all in less than two years since its formation.

Latest News

About Us

Tevogen Bio is driven by a team of distinguished scientists and experienced biopharmaceutical leaders who have developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from discovery to clinical phase within 18 months of inception, shaving years off the industry’s standard for drug development timelines.

Tevogen leadership believes that accessible personalized immunotherapies are the next frontier of medicine and disruptive business models are required to sustain medical innovation in the post-pandemic world. The company’s proprietary technology overcomes traditional barriers to the broad application of targeted T cell therapies through advances in speed to patient and product purity. Tevogen’s focus on organizational and manufacturing efficiency is core to its successful biopharma business model and the company’s goal is to make personalized immunotherapies accessible to the masses for the first time. Tevogen Bio’s research pipeline includes targeted CD8+ T Lymphocyte therapeutics for the treatment of common cancers and difficult to eradicate serious viral infections.

Our Innovative Science

Tevogen’s patented allogeneic T cell technology is a major scientific breakthrough   

ExacTcell™, Tevogen’s precision T cell platform, utilizes CD8+ Cytotoxic T Lymphocytes (CTLs) also known as Killer T Cells, one of nature’s most powerful weapons against cancer AND infection.

Unlike currently available genetically engineered T cell therapies, the ExacTcell platform is based on careful selection of naturally occurring T cells that recognize targets of interest from the body’s native T cell receptor pool to provide enhanced safety.

CD8+ CTLs in ExacTcell based products target multiple and distinct antigens to overcome potential mutational challenges.

Learn more about our Precision T Cells and their use in virology, oncology, and neurology


We are committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need

Investor Relations

Purpose, innovations, and opportunity to join before Tevogen’s next growth spurt

Contact ir@tevogen.com

Message From the CEO

Tevogen was created based on the audacious goal of finding a cure for cancer. This dream inspired us to pursue the development of life-saving therapies for some of the most prevalent illnesses plaguing humanity today.

Our success is rooted in passion and perseverance, and is backed by rigorous science. However, our unrelenting optimism – and belief that learning and adapting means improving – is what propelled us to this moment.

Our corporate culture encourages people to contribute their unique and diverse perspectives, to harness their optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose. We all are different and think differently, it’s okay to fail and make mistakes but learn from the failures – that mindset, respect for each other and irrational optimism is what has made Tevogen a reality.

I am confident in Tevogen’s success, and in our investigational therapies. We have brought together accomplished experts in immunotherapy and biopharma business to contribute their knowledge in a practical and efficient way. Tevogen is uniquely positioned to combat several large-scale health problems of today, including COVID-19. I am equally confident in our rapidly advancing and diverse research portfolio in virology, oncology, and neurology.

One of our objectives is to ensure that all people, regardless of socioeconomic status, are able to afford our therapies. Tevogen’s aim is to be the first biotech to offer personalized T cell therapeutics at commercially attractive and economically viable price. As the founder of Tevogen and its CEO, I am personally delighted to see that what started as an intrepid goal may very well play a critical role in overcoming the biggest public health crisis of our time.

Ryan Saadi, MD, MPH
CEO, Tevogen Bio

© 2023 Tevogen Bio. All Rights Reserved.